Chandra P Belani

Summary

Affiliation: Pennsylvania State University
Country: USA

Publications

  1. doi request reprint The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors
    Chandra P Belani
    Penn State Hershey Cancer Institute, Penn State Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA
    Cancer Invest 28:413-23. 2010
  2. doi request reprint Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
    C P Belani
    Penn State Hershey Cancer Institute, 500 University Drive, CH72, Hershey, PA 17033, USA
    Cancer Treat Rev 38:173-84. 2012
  3. pmc Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer
    Chandra P Belani
    Penn State Hershey Cancer Institute, Milton S Hershey Medical Center, Hershey, PA, USA
    Cancer Biol Ther 14:557-63. 2013
  4. doi request reprint Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study
    Chandra P Belani
    Penn State Hershey Cancer Institute, Hershey, PA 17033, USA
    Lancet Oncol 13:292-9. 2012
  5. doi request reprint Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer
    Chandra P Belani
    Penn State Cancer Institute, H072, 500 University Drive, PO Box 850, Hershey, PA 77030, USA
    J Clin Oncol 26:468-73. 2008
  6. ncbi request reprint The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: Overcoming resistance to reversible EGFR inhibitors
    Chandra P Belani
    Penn State Hershey Cancer Institute, Penn State Milton S Hershey Medical Center, 17033, USA
    Cancer Invest 120:413-23. 2010
  7. doi request reprint Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study
    Chandra P Belani
    Department of Medicine, Penn State Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania 17033 0850, USA
    Cancer 113:2512-7. 2008
  8. doi request reprint Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
  9. ncbi request reprint Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
  10. doi request reprint A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008

Collaborators

Detail Information

Publications89

  1. doi request reprint The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors
    Chandra P Belani
    Penn State Hershey Cancer Institute, Penn State Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA
    Cancer Invest 28:413-23. 2010
    ..Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are an emerging class of agents that may have the potential to overcome and prevent the emergence of such mutation-related resistance...
  2. doi request reprint Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
    C P Belani
    Penn State Hershey Cancer Institute, 500 University Drive, CH72, Hershey, PA 17033, USA
    Cancer Treat Rev 38:173-84. 2012
    ..This review outlines the rationale for combining targeted agents for the treatment of advanced NSCLC...
  3. pmc Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer
    Chandra P Belani
    Penn State Hershey Cancer Institute, Milton S Hershey Medical Center, Hershey, PA, USA
    Cancer Biol Ther 14:557-63. 2013
    ..Adding PF-3512676 to erlotinib did not show potential for increased progression-free survival over erlotinib alone in patients with advanced recurrent epidermal growth factor receptor-positive non-small cell lung cancer. ..
  4. doi request reprint Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study
    Chandra P Belani
    Penn State Hershey Cancer Institute, Hershey, PA 17033, USA
    Lancet Oncol 13:292-9. 2012
    ..Results for quality of life, symptom palliation, and tolerability are presented here...
  5. doi request reprint Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer
    Chandra P Belani
    Penn State Cancer Institute, H072, 500 University Drive, PO Box 850, Hershey, PA 77030, USA
    J Clin Oncol 26:468-73. 2008
    ....
  6. ncbi request reprint The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: Overcoming resistance to reversible EGFR inhibitors
    Chandra P Belani
    Penn State Hershey Cancer Institute, Penn State Milton S Hershey Medical Center, 17033, USA
    Cancer Invest 120:413-23. 2010
    ..Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are an emerging class of agents that may have the potential to overcome and prevent the emergence of such mutation-related resistance...
  7. doi request reprint Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study
    Chandra P Belani
    Department of Medicine, Penn State Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania 17033 0850, USA
    Cancer 113:2512-7. 2008
    ..Therefore, a phase 2 study was conducted to evaluate the efficacy of the combination of cetuximab, carboplatin, and docetaxel for the treatment of advanced NSCLC...
  8. doi request reprint Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  9. ncbi request reprint Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
    ..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel...
  10. doi request reprint A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
    ..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...
  11. ncbi request reprint Paclitaxel for non-small cell lung cancer
    Sakkaraiappan Ramalingam
    University of Pittsburgh School of Medicine, PA, USA
    Expert Opin Pharmacother 5:1771-80. 2004
    ..Paclitaxel has also demonstrated synergistic interaction with several molecularly-targeted agents and is at present being evaluated in the neoadjuvant and adjuvant treatment settings for early stage NSCLC...
  12. pmc Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 28:1520-6. 2010
    ..To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)...
  13. pmc Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells
    Taofeek K Owonikoko
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Int J Cancer 126:743-55. 2010
    ..This likely involves a vorinostat-mediated irreversible increase in DNA damage in the case of carboplatin and a reversible increase in microtubule stability in the case of paclitaxel...
  14. ncbi request reprint Taxanes for advanced non-small cell lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Expert Opin Pharmacother 3:1693-709. 2002
    ..Several ongoing trials are comparing the efficacy of combining molecularly targeted agents with taxane-based regimens for the treatment of advanced NSCLC...
  15. ncbi request reprint Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Cancer Res 13:1769-74. 2007
    ..The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week...
  16. pmc Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
    Abdulateef O Aregbe
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 W 10th Street, WD W7123, Indianapolis, IN 46202, USA
    Cancer Chemother Pharmacol 70:201-5. 2012
    ..To identify sources of exposure variability for the tumor growth inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) using a population pharmacokinetic analysis...
  17. doi request reprint Endobronchial valve placement for spontaneous pneumothorax from stage IIIA non-small cell lung cancer facilitates neoadjuvant therapy
    Christopher R Gilbert
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania Electronic address
    Ann Thorac Surg 96:2225-7. 2013
    ..Endobronchial valve placement allowed for the avoidance of pleurodesis, timely discharge, and neoadjuvant chemotherapy, followed by definitive surgical resection. ..
  18. ncbi request reprint Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study
    Sakkaraiappan Ramalingam
    Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 53:439-44. 2004
    ..To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer...
  19. ncbi request reprint Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    Mark G Kris
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 290:2149-58. 2003
    ....
  20. ncbi request reprint Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Semin Oncol 31:25-33. 2004
    ..Recent clinical data on new chemotherapeutic strategies for the treatment of lung, breast, and genitourinary cancers and myeloma will be presented in this review...
  21. ncbi request reprint Role of bevacizumab for the treatment of non-small-cell lung cancer
    Suresh Ramalingam
    Division of Hematolgoy Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Future Oncol 3:131-9. 2007
    ..This article discusses the recent data with bevacizumab in NSCLC and its potential application at various stages of NSCLC...
  22. ncbi request reprint A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:2109-14. 2007
    ..Objectives of this study were to determine safety, tolerability, pharmacodynamics, and pharmacokinetics of PX-12, a small-molecule inhibitor of Trx-1...
  23. ncbi request reprint Emerging advances in the management of lung cancer
    Chandra P Belani
    Department of Medicine, University of Pittsburgh School of Medicine, PA 15232, USA
    Clin Lung Cancer 6:S60. 2004
  24. ncbi request reprint Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
    ..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination...
  25. doi request reprint A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 64:777-83. 2009
    ..To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC)...
  26. ncbi request reprint Recent advances in targeted therapy for non-small cell lung cancer
    Suresh Ramalingam
    University of Pittsburgh School of Medicine, Division of Hematology Oncology, Department of Medicine, Pittsburgh, PA, USA
    Expert Opin Ther Targets 11:245-57. 2007
    ..These developments have paved the way for a new era of tailor-made therapies based on clinical or molecular/genetic profiles in the treatment of NSCLC. This article reviews the recent advances in targeted therapy of advanced NSCLC...
  27. ncbi request reprint Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
    ..The pharmacokinetics of MGd were also evaluated...
  28. ncbi request reprint Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
    J Thorac Oncol 1:441-6. 2006
    ..E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy...
  29. ncbi request reprint Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer
    Chandra P Belani
    Department of Medicine, University of Pittsburgh School of Medicine, PA 15232, USA
    Clin Lung Cancer 6:S6. 2004
  30. pmc Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer
    Hong Zheng
    Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, USA
    Oncotarget 7:56233-56240. 2016
    ..This work highlights the potential of a non-invasive and effective method to determine prognostic and predictive biomarkers for inhibiting the PD-1 pathway in NSCLC patients...
  31. ncbi request reprint Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
    Shawn J Rice
    Penn State Hershey Cancer Institute, Penn State College of Medicine, 500 University Dr, Hershey, PA 17033, USA
    Curr Mol Pharmacol 9:183-195. 2016
    ..The durability of clinical activity in a subset of patients has led to a great deal of excitement and optimism...
  32. ncbi request reprint Molecularly-targeted therapies for non-small cell lung cancer
    Suresh Ramalingam
    Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Expert Opin Pharmacother 6:2667-79. 2005
    ..The exciting results of this study represent an important advance in the treatment of patients with advanced NSCLC...
  33. pmc Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building
    Eric A Sherer
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    J Pharmacokinet Pharmacodyn 39:393-414. 2012
    ....
  34. doi request reprint Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung
    Shawn J Rice
    Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, USA
    Proteomics 15:3267-77. 2015
    ..Our analysis reveals that elevated plasma APOE is associated with smoking, and APOE is a novel predictive protein biomarker for early morphological changes of squamous metaplasia in the lung. ..
  35. doi request reprint Small-cell lung cancer: an update on targeted therapies
    Monika Joshi
    Department of Medicine, Penn State Hershey Medical Center, 500 University Drive, CH72, Hershey, PA 17033, USA
    Adv Exp Med Biol 779:385-404. 2013
    ..Novel and targeted agents have been evaluated but without much success. Increasing understanding of the biology and potential clinical evaluation of biomarkers will pave the way for more effective treatments...
  36. doi request reprint Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update
    Ayodele Ayoola
    Penn State Hershey Cancer Institute, Penn State Milton S Hershey Medical Center, Hershey, PA 17033, USA
    Cancer Invest 30:433-46. 2012
    ..There are many novel targeting agents in development to overcome resistance to EGFR TKIs...
  37. pmc Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)
    Chandra P Belani
    Penn State Hershey Cancer Institute, Hershey, Pennsylvania
    Cancer 122:2371-8. 2016
    ....
  38. pmc Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer
    Monika Joshi
    Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States of America
    PLoS ONE 10:e0118210. 2015
    ..This finding suggests that, the combination of a MEK inhibitor with a BRAF inhibitor will be more efficacious in the clinical setting for patients with BRAF mutated NSCLC. ..
  39. doi request reprint Taxanes, past, present, and future impact on non-small cell lung cancer
    Monika Joshi
    Department of Medicine, Division of Medical Oncology, Penn State College of Medicine, Hershey, Pennsylvania, USA
    Anticancer Drugs 25:571-83. 2014
    ..Oral formulations of paclitaxel and docetaxel are of great interest, but have yet to receive regulatory approval in this disease. The phase I-II trials have shown that these formulations are feasible in the clinical setting. ..
  40. ncbi request reprint Meaningful survival in lung cancer patients
    Sakkaraiappan Ramalingam
    Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Semin Oncol 29:125-31. 2002
    ..In this review, we discuss the impact of anemia and the treatment options that could contribute to a truly meaningful survival in lung cancer patients...
  41. doi request reprint Volociximab in cancer
    Salah Almokadem
    Penn State Hershey Medical Center, Department of Medicine, Hershey, PA, USA
    Expert Opin Biol Ther 12:251-7. 2012
    ..In this review we focus on the biological effect of volociximab and results of completed clinical trials...
  42. doi request reprint Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation
    Monika Joshi
    Penn State Hershey Medical Center, Department of Medicine, Hershey, PA, USA
    Expert Opin Pharmacother 13:685-97. 2012
    ..Several randomized studies have been conducted to find out the usefulness of maintenance therapies for advanced non-small-cell lung cancer (NSCLC)...
  43. doi request reprint Multidisciplinary management of malignant pleural effusion
    Jussuf T Kaifi
    Section of Surgical Oncology, Department of Surgery, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania, USA
    J Surg Oncol 105:731-8. 2012
    ..The treatment for each patient should be based on symptoms, general condition, and life expectancy...
  44. pmc Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  45. ncbi request reprint Development of docetaxel in advanced non-small-cell lung cancer
    Chandra P Belani
    University of Pittsburgh School of Medicine, and Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Lung Cancer 46:S3-11. 2004
    ..Non-platinum doublets such as docetaxel-gemcitabine have also demonstrated efficacy and safety. Docetaxel has undergone extensive evaluation and is the only agent approved for use in both first- and second-line therapy of advanced NSCLC...
  46. doi request reprint Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm
    Arjun Pennathur
    Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Ann Thorac Surg 85:1930-6; discussion 1936-7. 2008
    ..We report the long-term results of our phase II study of neoadjuvant chemotherapy, followed by esophagectomy and adjuvant chemotherapy for potentially resectable esophageal carcinoma...
  47. doi request reprint Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer
    Suresh Ramalingam
    Emory Winship Cancer Institute, Atlanta, Georgia, USA
    Cancer 113:542-6. 2008
    ....
  48. ncbi request reprint Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)
    Chandra P Belani
    Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, PA 15232, USA
    Cancer 104:2766-74. 2005
    ..DC and docetaxel-carboplatin (DCb) were better tolerated than VC. We analyzed the efficacy and toxicity in patients ages < 65 and > or = 65 years...
  49. ncbi request reprint Combining targeted agents in lung cancer
    Chandra P Belani
    Clin Lung Cancer 6:138. 2004
  50. ncbi request reprint Carboplatin/gemcitabine combination in advanced NSCLC
    Sakkaraiappan Ramalingam
    University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA
    Oncology (Williston Park) 18:21-6. 2004
    ..This regimen can also be used as a foundation for the development of innovative combinations with molecularly targeted agents...
  51. ncbi request reprint Basic treatment considerations: chemotherapy
    Sakkaraiappan Ramalingam
    Division of Hematology Oncology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
    Hematol Oncol Clin North Am 18:13-28. 2004
    ..In the upcoming years, we will learn effective means to incorporate molecularly targeted therapies to existing treatment paradigms in lung cancer...
  52. ncbi request reprint State-of-the-art chemotherapy for advanced non-small cell lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology Oncology, University of Pittsburgh School of Medicine, PA 15232, USA
    Semin Oncol 31:68-74. 2004
    ..Noncytotoxic, molecularly targeted agents currently under various phases of development for the treatment of lung cancer will serve as the cornerstones for further innovations in the treatment of NSCLC...
  53. ncbi request reprint Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology Oncology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, PA 15232, USA
    Semin Thorac Cardiovasc Surg 15:438-47. 2003
    ..Early results with some of the targeted agents studied for the treatment of NSCLC have generated a great deal of excitement. In this article, we review the results of recent clinical trials in locally advanced and metastatic NSCLC...
  54. ncbi request reprint Early-stage non-small-cell lung cancer: adjuvant versus neoadjuvant chemotherapy
    Chandra P Belani
    Clin Lung Cancer 5:11-2. 2003
  55. ncbi request reprint Elderly patients with advanced non-small-cell lung cancer
    Chandra P Belani
    Clin Lung Cancer 5:76. 2003
  56. ncbi request reprint Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation
    Chandra P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 21:2933-9. 2003
    ....
  57. ncbi request reprint Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
    Frank Fossella
    Division of Medical Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Center Ave, Suite 570, Pittsburgh, PA 15232, USA
    J Clin Oncol 21:3016-24. 2003
    ..To investigate whether docetaxel plus platinum regimens improve survival and affect quality of life (QoL) in advanced non-small-cell lung cancer (NSCLC) compared with vinorelbine plus cisplatin as first-line chemotherapy...
  58. ncbi request reprint First-line chemotherapy for NSCLC: an overview of relevant trials
    Chandra P Belani
    Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute and School of Medicine, UPMC Cancer Pavilion, 5150 Centre Avenue 5th Floor, Pittsburgh, PA 15232, USA
    Lung Cancer 38:13-9. 2002
    ..Hopes for further improvement in survival are focused on the combination of cytotoxic agents with novel molecularly-targeted drugs such as the anti-angiogenics and EGFR inhibitors...
  59. ncbi request reprint Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer
    Chandra P Belani
    Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, PA
    Semin Oncol 29:4-9. 2002
    ....
  60. ncbi request reprint Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
    ..We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer...
  61. ncbi request reprint Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lu
    Chandra P Belani
    University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    J Clin Oncol 23:3760-7. 2005
    ..To compare once-daily radiation therapy (qdRT) with hyperfractionated accelerated radiation therapy (HART) after two cycles of induction chemotherapy...
  62. ncbi request reprint Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy
    Michal J Wolski
    Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Lung Cancer 7:100-6. 2005
    ..Three-dimensional (3D) conformal radiation therapy (CRT) and chemotherapy have recently improved lung cancer management...
  63. ncbi request reprint Optimizing first-line treatment options for patients with advanced NSCLC
    Heather Wakelee
    Stanford University, Stanford, California, USA
    Oncologist 10:1-10. 2005
    ..Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC...
  64. ncbi request reprint Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Lung Cancer 50:S3-8. 2005
    ..Based on the efficacy of platin-docetaxel regimens in advanced disease, they are now being incorporated into the adjuvant and neoadjuvant treatment of early-stage disease...
  65. ncbi request reprint Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial
    Chandra P Belani
    University of Pittsburgh School of Medicine, Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, Cancer Pavilion, Floor 5, 5150 Centre Avenue Pittsburgh, PA 15232, USA
    Lung Cancer 53:231-9. 2006
    ..We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin...
  66. ncbi request reprint PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2
    Kathy S Albain
    Loyola University, Chicago Medical Center, Maywood, IL 60153, USA
    Clin Lung Cancer 7:417-9. 2006
  67. ncbi request reprint Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol
    Chandra P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 23:5883-91. 2005
    ..Survival data were compared with historical standard sequential chemoradiotherapy data from the Radiation Therapy Oncology Group...
  68. ncbi request reprint The ANITA trial seals the deal for adjuvant therapy in non-small-cell lung cancer
    Chandra P Belani
    Clin Lung Cancer 6:331-2. 2005
  69. ncbi request reprint Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer
    Chandra P Belani
    Clin Lung Cancer 6:267-8. 2005
  70. ncbi request reprint Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial
    Suresh Ramalingam
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    J Thorac Oncol 1:240-4. 2006
    ....
  71. ncbi request reprint Docetaxel in advanced non-small cell lung cancer
    Heather Wakelee
    Stanford University School of Medicine, Stanford University Cancer Center, 875 Blake Wilbur Dr, Stanford, CA 94305 5826, USA
    Expert Rev Anticancer Ther 5:13-24. 2005
    ..This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC...
  72. ncbi request reprint Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database
    Taofeek K Owonikoko
    Emory Winship Cancer Institute, 1365 Clifton Rd, Ste C 5090, Atlanta, GA 30322, USA
    J Clin Oncol 25:5570-7. 2007
    ..To study the burden and outcome of lung cancer in the elderly, particularly for patients aged 80 years and older...
  73. ncbi request reprint Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    Roy S Herbst
    The M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4743-50. 2007
    ..A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile...
  74. ncbi request reprint Adjuvant and neoadjuvant therapy in non-small cell lung cancer
    Chandra P Belani
    Lung and Thoracic Cancer Program, University Cancer Institute, University of Pittsburgh School of Medicine, UPMC Cancer Pavilion, 5150 Center Avenue 5th Floor, Pittsburgh, PA 15232, USA
    Semin Oncol 32:S9-15. 2005
    ..Neoadjuvant chemotherapy may also downstage the disease before surgery and decrease perioperative tumor seeding, and molecularly targeted approaches with neoadjuvant therapy appear promising...
  75. ncbi request reprint Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer
    John V Heymach
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:4270-7. 2007
    ..The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC)...
  76. ncbi request reprint Lung cancer: looking ahead in 2004
    Chandra P Belani
    Clin Lung Cancer 5:200. 2004
  77. doi request reprint Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study
    Suresh Ramalingam
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    J Thorac Oncol 3:258-64. 2008
    ....
  78. ncbi request reprint Ongoing and future trials of biologic therapies in lung cancer
    Paul A Bunn
    University of Colorado Cancer Center, Denver, CO, USA
    Lung Cancer 41:S175-86. 2003
    ..Many new agents have been developed to attack these targets. This article describes current and proposed trials for these new targeted therapies in both small cell and non-small cell lung cancers...
  79. ncbi request reprint Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
    Ramaswamy Govindan
    Washington University School of Medicine, Department of Medical Oncology, 660 S Euclid Ave Box 8056, St Louis, MO 63110, USA
    Lung Cancer 53:331-7. 2006
    ..3%). Complete and partial response rates were 0.7 and 5.6%, respectively, and 40.6% had stable disease. Median survival was 6 months, and estimated 1-year survival was 29.7%. The majority of patients did not receive subsequent CT...
  80. ncbi request reprint Integration of docetaxel in the management of non-small-cell lung cancer
    Chandra P Belani
    University of Pittsburgh School of Medicine, and Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Lung Cancer 46:S1-2. 2004
  81. ncbi request reprint Molecular predictors of sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor: confusion or clarity?
    Chandra P Belani
    Clin Lung Cancer 7:8. 2005
  82. doi request reprint Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial
    Y Yen
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Am J Clin Oncol 31:317-22. 2008
    ..Oxaliplatin has recently demonstrated activity in HCC. The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin...
  83. ncbi request reprint Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Lung Cancer 6:43-7. 2004
    ..There were 3 early deaths associated with the treatment regimen: severe gastrointestinal toxicity, hemorrhage, and an acute pulmonary event. Docetaxel as a single agent does not demonstrate evidence of activity in malignant mesothelioma...
  84. ncbi request reprint Cyclooxygenase-2 inhibitors in lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology Oncology, Lung and Thoracic Cancer Program, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, PA 15323, USA
    Clin Lung Cancer 5:245-53. 2004
    ..These effects have been documented in several preclinical studies. Clinical efficacy of COX-2 inhibitors in the treatment of NSCLC is presently undergoing evaluation...
  85. ncbi request reprint Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib
    Chandra P Belani
    Clin Lung Cancer 6:203-4. 2005
  86. ncbi request reprint Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial
    David Cella
    Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Ste 100, Evanston, IL 60201, USA
    J Clin Oncol 23:2946-54. 2005
    ..Among these NSCLC patients treated with gefitinib, symptom improvement was complementary to and, for most patients, preceded evidence of radiographic regression...
  87. ncbi request reprint Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thorac Oncol 1:506-12. 2006
    ..To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP)...
  88. ncbi request reprint Epidermal growth factor receptor mutations: a new insight
    Chandra P Belani
    Clin Lung Cancer 5:328. 2004
  89. ncbi request reprint Neoadjuvant versus adjuvant therapy for resectable non-small-cell lung cancer
    Chandra P Belani
    Clin Lung Cancer 6:8. 2004